U.S., Jan. 13 -- ClinicalTrials.gov registry received information related to the study (NCT07333651) titled '125I Seed Implantation Plus Systemic Therapy for Oligoprogressive NSCLC or Colorectal Cancer' on Dec. 16, 2025.
Brief Summary: Most patients with metastatic cancer eventually develop resistance to systemic therapy. A subset of patients experience oligoprogression, characterized by progression at a limited number of lesions while other disease sites remain controlled by ongoing systemic therapy. This randomized phase 2 trial evaluates whether image-guided 125I seed implantation targeting all oligoprogressive extracranial lesions, combined with standard-of-care systemic therapy, improves progression-free survival compared with standar...